NCT02273388 2023-10-03
BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
Clinical Trials
9 trialsNCT01772563 2023-09-01
Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT01206816 2019-02-01
An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT00969761 2019-01-31
BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour
Boehringer Ingelheim
Phase 1 Completed
NCT01145885 2019-01-31
BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT01348347 2018-08-06
BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT01022853 2018-07-30
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT01971476 2018-07-30
Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known
Boehringer Ingelheim
Phase 1 Completed
NCT01023958 2017-11-22
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
Boehringer Ingelheim
Phase 2 Completed